Actinogen Medical Limited
ATGGF
$0.025
$0.00525.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 129.17% | 123.51% | -10.30% |
| Total Revenue | -- | -- | 129.17% | 123.51% | -10.30% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 129.17% | 123.51% | -10.30% |
| SG&A Expenses | 5.24% | 7.70% | 3.22% | 0.66% | 16.12% |
| Depreciation & Amortization | -4.49% | -2.16% | -1.17% | -3.58% | 4.54% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.45% | -31.89% | 41.87% | 38.37% | 46.71% |
| Operating Income | 28.26% | 26.58% | 54.88% | 56.00% | -54.36% |
| Income Before Tax | 29.32% | 27.67% | 55.71% | 56.80% | -53.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.32% | 27.67% | 55.71% | 56.80% | -53.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.32% | 27.67% | 55.71% | 56.80% | -53.95% |
| EBIT | 28.26% | 26.58% | 54.88% | 56.00% | -54.36% |
| EBITDA | 28.60% | 26.93% | 57.49% | 58.54% | -55.43% |
| EPS Basic | 50.00% | 50.00% | 66.67% | 66.67% | -38.46% |
| Normalized Basic EPS | 45.45% | 45.45% | 75.00% | 75.00% | -37.50% |
| EPS Diluted | 50.00% | 50.00% | 66.67% | 66.67% | -38.46% |
| Normalized Diluted EPS | 45.45% | 45.45% | 75.00% | 75.00% | -37.50% |
| Average Basic Shares Outstanding | 41.37% | 41.37% | 27.74% | 27.74% | 13.74% |
| Average Diluted Shares Outstanding | 41.37% | 41.37% | 27.74% | 27.74% | 13.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |